Seeking Alpha

Seeking Alpha Portfolio App for iPad

626 people get CBLI articles and Market Currents by email alert.

Get email alerts on CBLI »

CBLI

Cleveland BioLabs, Inc.

5/22/2013, 10:07 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 12:51 PM Cleveland BioLabs (CBLI +3.3%) gains today after saying that it and Incuron, a joint venture between the company and Bioprocess Capital Ventures, have received patent approval from the USPTO for Curaxin. The European Patent Office also signed off on a patent for New Zealand, South Africa, and Kazhakstan recently, while the Russian Federation issued one as well. Comment! [Healthcare, On the Move, Global & FX]
Thursday, May 9, 9:46 AM Cleveland BioLabs (CBLI): Q1 EPS of -$0.22 misses by $0.05. Revenue of $1.37M misses by $0.36M. (PR) Comment! [Earnings, Breaking News]
Thursday, April 4, 12:17 PM Cleveland BioLabs (CBLI +2%) moves up today on slightly heavier-than-usual volumes, possibly getting a boost from North Korea's ramped up nuclear threats and the fact that the company is working on a medical radiation countermeasure, Entolimod. The company also announced late Tuesday that it had received a Notice of Allowance from the FDA for an investigational new drug application for CBL0137. Comment! [Healthcare, On the Move, Global & FX]
Tuesday, April 2, 12:38 PM Cleveland BioLabs (CBLI +2%) moves up after saying that it and Incuron, a joint venture between the CBLI and Bioprocess Capital Ventures, have received a Notice of Allowance from the FDA for an Investigational New Drug application for CBL0137, a treatment for patients with metastatic or unresectable advanced solid cancers. A Phase 1 dosing trials to evaluate the drug's intravenous administration are currently being finalized with the agency. Comment! [Healthcare, On the Move]
Thursday, March 21, 9:10 AM Premarket gainers: ITMN +12%. CBLI +9%. ACAD +7%. AFFY +6%.
Losers: CIMT -12%. SCHL -11%. BLDP -9%. ORCL -8%. GES -7%. Comment! [On the Move]
Wednesday, March 20, 8:01 PM Cleveland BioLabs (CBLI) gets a lift during the post-session after Cantor Fitzgerald initiated the shares late in the day with a Buy rating and a hefty $4 price target. Cantor says the stock has been depressed by several overhangs that have caused it to lag its peers. Once that pressure is eliminated, the shares should trade at a higher valuation more closely aligned to its peers. Shares +6.7% AH. Comment! [Healthcare, On the Move]
Friday, October 19, 2012, 12:45 PM Midday top 10 gainers: GURE +18%. RVBD +13%. CALL +12%. EFUT +10%. MAN +9%. NCTY +9%. FWRD +8%. USCR +8%. XIN +7%. CCIH +6%.
Top 10 Losers: CBLI -24%. PXLW -22%. MIG -21%. ZIOP -17%. VOC -15%. CMG -15%. MRVL -14%. AMD -14%. BGMD -14%. CEMP -13%. Comment! [On the Move]
Friday, October 19, 2012, 9:10 AM Premarket gainers: SVNT +12%. RVBD +11%. CALL +7%. SNDK +7%.
Losers: CBLI -20%. ATHN -11%. CMG -11%. MRVL -9%. PH -9%. ETFC -6%. Comment! [On the Move]
Thursday, October 18, 2012, 3:47 PM Cleveland BioLabs (CBLI +2%) gains after submitting a proposal to the Department of Health and Human Services for funding of the remaining steps needed for government approval of Entolimod as a medical radiation countermeasure. The proposal is based on FDA feedback regarding the pivotal programs and animal-to-human dose conversion, and is intended to address points of concern noted by BARDA in connection with its previous Entolimod proposal. 1 Comment [Healthcare, On the Move]
Tuesday, October 2, 2012, 9:07 AM The FDA grants orphan-drug status to curaxin CBL0102, which is being developed by a Russian JV of Cleveland BioLabs (CBLI +6.5%) and Bioprocess Capital Ventures for treating hepatocellular carcinoma, a type of liver cancer. The disease affects around 30K people in the U.S. and 45K in the EU each year, and the survival rate is 15%. A Phase I trial of CBL0102 is being carried out in Russia. (PR) Comment! [On the Move, Healthcare]
Monday, October 1, 2012, 3:20 PM Cleveland BioLabs (CBLI -3%) slips after saying it's received the end-of-Phase 2 meeting minutes from the FDA, along with an advice letter which clarifies the remaining clinical study protocols for the development of its Entolimod as a radiation countermeasure. The firm says the agency is committed to moving the Entolimod program forward, but it has some requests regarding several aspects of the proposed plan for dose conversion. 1 Comment [Healthcare, On the Move]
Tuesday, June 5, 2012, 10:50 AM Cleveland BioLabs (CBLI -12.5%) gives back some ground this morning after yesterday's +50% surge following the announcement that its treatment for radiation sickness yielded strong survival results in a study of 179 nonhuman primates. Comment! [Healthcare, On the Move]
Wednesday, April 4, 2012, 9:17 AM Cleveland BioLabs (CBLI) -24.3% premarket after announcing BARDA has declined to invite submission of a full proposal for continued development funding of CBLB502 as a drug candidate to protect healthy tissues from acute stresses such as radiation and chemotherapy. Comment! [Healthcare, On the Move]
Monday, September 26, 2011, 11:42 AM Cleveland BioLabs (CBLI +5.8%) trades up after saying Russian investment firm Rusnano will spend up to $26M over the next four years to help fund a new company unit that will develop a portfolio of new preclinical drug candidates. Comment! [Healthcare, On the Move]
Friday, June 17, 2011, 9:14 AM Cleveland BioLabs (CBLI) says it will sell almost 9M shares to raise $23.5M. For $4, buyers get one common share, and warrants to buy half a share at $4.50 and $5.00 for the next 1-5 years. CBLI -14% premarket to $3.81. (PR) Comment! [Breaking News, Healthcare, On the Move]
Friday, June 17, 2011, 9:00 AM Premarket gainers: ZRAN +21%. NCT +18%. HRBN +16%. SPRD +9%. NBG +8%. DANG +6%. YOKU +6%. BBVA +5%. PRMW +6%. CTIC +5%. STD +5%. RENN +4%. TEF +4%. NOK +4%. ING +3%. BJ +3%. DB +3%. ALU +3%. DRYS +3%. BIDU +3%. SNY +3%.
Losers: RIMM -16%. CBLI -15%. MIND -9%. LPL -6%. CHU -4%. WACLY -3%. Comment! [On the Move]